Next Article in Journal
A Feasibility Study of Personalized Prescription Schemes for Glioblastoma Patients Using a Proliferation and Invasion Glioma Model
Previous Article in Journal
Targeting Intracellular Calcium Signaling ([Ca2+]i) to Overcome Acquired Multidrug Resistance of Cancer Cells: A Mini-Overview
Previous Article in Special Issue
Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview
Cancers 2017, 9(5), 50; doi:10.3390/cancers9050050

Immunotherapy for Colorectal Cancer

1
Roswell Park Cancer Institute, Department of Medicine, Elm and Carlton St, Buffalo, NY 14263, USA
2
Mayo Clinic, Division of Medical Oncology, 200 First St. SW, Rochester, MN 55905, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Vita Golubovskaya
Received: 15 February 2017 / Revised: 5 May 2017 / Accepted: 5 May 2017 / Published: 11 May 2017
(This article belongs to the Special Issue Cancer Immunotherapies)
View Full-Text   |   Download PDF [208 KB, uploaded 11 May 2017]

Abstract

The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors. View Full-Text
Keywords: colon cancer; immunotherapy; anti-PD1 colon cancer; immunotherapy; anti-PD1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Boland, P.M.; Ma, W.W. Immunotherapy for Colorectal Cancer. Cancers 2017, 9, 50.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top